ZBIO Zenas BioPharma, Inc.
$27.73▲ +1.80%
Healthcare
Other
Volume 97.6K
Avg Volume (10D) 496.3K
Key Metrics & Fundamentals
Market Cap
$1.81B
P/E Ratio
–
Div Yield
0.00%
52W Range
13.50 - 44.60
% vs 50 MA
-8.34%
% vs 200 MA
9.89%
RSI-14
47.4
MACD Histogram
+0.3000
Beta (1Y vs SPY)
0.47
Free Cash Flow
-$87.24M
Gross Rev
$1.00M
Gross Profit
$1.00M
EBITDA
-$71.04M
COGS
–
Operating Exp
$78.66M
Operating Income
-$77.66M
EBIT
-$77.66M
Pretax Income
-$111.34M
Net Income
-$111.46M
EPS (Diluted)
-1.77
Price & Volume History
Loading chart…
Recent News
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
Zacks · Oct 23, 2026 8:55 AM ET
Zenas BioPharma Stock Gains Attention After Long Term Trial Data
Simply Wall St. · Oct 20, 2026 8:17 PM ET
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 16, 2026 4:15 PM ET
Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release
Simply Wall St. · Oct 13, 2026 4:18 AM ET
Zenas BioPharma Reports New Obexelimab Data in IgG4-Related Disease
MT Newswires · Oct 12, 2026 7:38 AM ET
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
GlobeNewswire · Oct 12, 2026 7:00 AM ET
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
GlobeNewswire · Oct 7, 2026 7:05 AM ET
Zenas BioPharma to Host Virtual R&D Event
GlobeNewswire · Oct 6, 2026 7:05 AM ET
Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says
MT Newswires · Sep 30, 2026 11:33 AM ET
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
Insider Monkey · Sep 23, 2026 7:14 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ZBIO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.